Apellis Pharmaceuticals Inc (APLS) — Cash Flow Quality Index

Latest as of March 2026: -3.27x

Apellis Pharmaceuticals Inc (APLS) has a Cash Flow Quality Index of -3.27x as of March 2026. Operating cash flow of $-60.97 Million is below net income of $18.66 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Apellis Pharmaceuticals Inc (APLS) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-3.27x
Operating CF / Net Income

Operating Cash Flow

$-60.97 Million
USD

Net Income

$18.66 Million
USD

Data as of

Mar 2026
Most recent filing

Apellis Pharmaceuticals Inc Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Apellis Pharmaceuticals Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Apellis Pharmaceuticals Inc (APLS) cash flow conversion.

Annual Cash Flow Quality Index for Apellis Pharmaceuticals Inc (2025–2025)

Year-by-year earnings quality comparison for Apellis Pharmaceuticals Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 2.02x $45.33 Million $22.39 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.